Back to top
more

Canopy Growth (CGC)

(Delayed Data from NSDQ)

$4.86 USD

4.86
4,473,269

+0.27 (5.88%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $4.86 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

What's in Store for Canopy Growth (CGC) in Q2 Earnings?

Canopy Growth's (CGC) newly-added Ace Valley and Supreme Cannabis hold part of the company's market share in fiscal Q2.

Clover Health (CLOV) to Report Q3 Earnings: What's in Store?

Clover Health's (CLOV) third-quarter results are likely to benefit from Direct Contracting and strategic partnerships.

Canopy Growth Corporation (CGC) Expected to Beat Earnings Estimates: Should You Buy?

Canopy Growth Corporation (CGC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Humana (HUM) to Post Q3 Earnings: What's in the Cards?

Humana's (HUM) third-quarter earnings are expected to have gained from higher revenues and a solid contribution from its Retail and Healthcare Services segments.

Canopy Growth Corporation (CGC) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Canopy Growth Corporation (CGC) closed at $13.01, marking a +1.76% move from the previous day.

Urmimala Biswas headshot

4 Medical Products Stocks Poised to Beat This Earnings Season

Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.

AmerisourceBergen (ABC) to Post Q4 Earnings: What's in Store?

AmerisourceBergen's (ABC) fiscal fourth-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

DENTSPLY SIRONA (XRAY) to Post Q3 Earnings: What's in Store?

DENTSPLY SIRONA (XRAY) third-quarter results are likely to reflect strong segmental performance.

Conformis (CFMS) to Post Q3 Earnings: What's in the Offing?

Conformis' (CFMS) third-quarter results are likely to reflect strength in core products.

PerkinElmer (PKI) to Post Q3 Earnings: What's in the Cards?

PerkinElmer's (PKI) third-quarter results are likely to reflect strong performance at the Diagnostics segment.

McKesson (MCK) to Report Q2 Earnings: What's in the Cards?

McKesson's (MCK) fiscal second-quarter results are likely to reflect the solid show by the U.S. Pharmaceutical and Specialty Solutions segment.

Cerner (CERN) to Report Q3 Earnings: What's in the Offing?

Cerner's (CERN) third-quarter results are likely to reflect gains from strategic deals.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Baxter (BAX) to Report Q3 Earnings: What's in the Offing?

Baxter's (BAX) third-quarter results are likely to reflect growth in its Acute Therapies business.

DexCom (DXCM) to Report Q3 Earnings: What's in the Cards?

DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

What's in Store for West Pharmaceutical's (WST) Q3 Earnings?

West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business.

Canopy Growth Corporation (CGC) Moves 8.6% Higher: Will This Strength Last?

Canopy Growth Corporation (CGC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Canopy Growth Corporation (CGC) Reports Q1 Loss, Tops Revenue Estimates

Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of 27.78% and 3.95%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know

In the latest trading session, Canopy Growth Corporation (CGC) closed at $18.80, marking a -0.58% move from the previous day.

Canopy Growth (CGC) to Report in Q1 Earnings: What's in Store?

Continued robust product demand is expected to have significantly contributed to Canopy Growth's (CGC) top line in the fiscal first quarter.

Will Canopy Growth Corporation (CGC) Report Negative Earnings Next Week? What You Should Know

Canopy Growth Corporation (CGC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Madeleine Johnson headshot

Why Cannabis Giant Tilray (TLRY) Skyrocketed Today

Shares of Tilray (TLRY) closed sharply higher in Wednesday's trading session, gaining 25.8% after reporting mixed fourth-quarter earnings results.

Canopy Growth Corporation (CGC) Dips More Than Broader Markets: What You Should Know

Canopy Growth Corporation (CGC) closed the most recent trading day at $23.91, moving -0.87% from the previous trading session.

Benjamin Rains headshot

Forget Meme Stocks: Buy These Strong Growth Stocks with Big Upside

Investors might want to consider adding growth focused stocks to their portfolios that are still trading below their highs, even as the meme stocks soar once again...

Company News for Jun 2, 2021

Companies In The News Are: ABT, CLDR, KKR, CGC, NIO.